Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 11.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,719 shares of the medical instruments supplier’s stock after purchasing an additional 395 shares during the quarter. Snowden Capital Advisors LLC’s holdings in Becton, Dickinson and Company were worth $844,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Siemens Fonds Invest GmbH raised its stake in Becton, Dickinson and Company by 1,328.2% during the fourth quarter. Siemens Fonds Invest GmbH now owns 219,222 shares of the medical instruments supplier’s stock valued at $49,735,000 after buying an additional 203,873 shares in the last quarter. Shell Asset Management Co. increased its holdings in shares of Becton, Dickinson and Company by 4.7% in the 4th quarter. Shell Asset Management Co. now owns 3,415 shares of the medical instruments supplier’s stock valued at $775,000 after acquiring an additional 153 shares during the last quarter. Silvercrest Asset Management Group LLC raised its position in shares of Becton, Dickinson and Company by 4.1% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 5,028 shares of the medical instruments supplier’s stock valued at $1,141,000 after acquiring an additional 200 shares in the last quarter. Rafferty Asset Management LLC boosted its holdings in Becton, Dickinson and Company by 11.8% in the fourth quarter. Rafferty Asset Management LLC now owns 32,777 shares of the medical instruments supplier’s stock worth $7,436,000 after purchasing an additional 3,461 shares during the period. Finally, Raiffeisen Bank International AG bought a new stake in Becton, Dickinson and Company during the fourth quarter valued at $34,608,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.9%

BDX opened at $177.06 on Tuesday. The stock’s 50 day moving average price is $202.67 and its 200 day moving average price is $220.31. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The stock has a market cap of $50.75 billion, a P/E ratio of 29.41, a P/E/G ratio of 1.63 and a beta of 0.31. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The company’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business earned $3.17 earnings per share. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.35%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 79.39%.

Becton, Dickinson and Company declared that its board has initiated a stock buyback program on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus lowered their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company lowered Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 1st. Piper Sandler downgraded Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. William Blair lowered Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Finally, Barclays dropped their target price on Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating on the stock in a research report on Monday, April 7th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $231.44.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the transaction, the executive vice president now directly owns 4,887 shares of the company’s stock, valued at $964,107.36. The trade was a 8.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard Byrd sold 459 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total transaction of $105,570.00. Following the completion of the sale, the executive vice president now owns 6,952 shares in the company, valued at approximately $1,598,960. This trade represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,878 shares of company stock worth $636,393 over the last quarter. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.